- About
- About bilaterals.org
-
Announcements
- Dec-2006: bilaterals.org in Spanish & French
- Feb-2016: New ISDS platform launched
- Sep-2004: Launch announcement
- Feb-2015: Relaunch of bilaterals.org
- Mar-2013: Relaunch of bilaterals.org
- Jun-2009: Relaunch of bilaterals.org
- Dec-2008: An update from bilaterals.org and logo design contest announcement
- Sep-2006: Update from bilaterals.org
- Help
- How to participate
- Negotiations
- Key issues
- Texts of agreements
- Links




NAFTA 2.0: US-Mexico-Canada Agreement. Chapter 20: pharmaceutical related patent provisions
posted 5-December-2018
All the versions of this article: [English] [Español]
Public Citizen | 4 December 2018
NAFTA 2.0: US-Mexico-Canada Agreement. Chapter 20: pharmaceutical related patent provisions
The Intellectual Property (IP) Chapter of the revised North American Free Trade Agreement (NAFTA 2.0), rebranded by the Trump Administration as the U.S.-Mexico-Canada Agreement or USMCA, includes provisions that threaten to undermine critical efforts towards affordable health care and medicine.
The NAFTA 2.0 text that was published Sept. 30 includes significant and harmful changes to the original NAFTA intellectual property (IP) provisions. These build on concepts included in other U.S. free trade agreements on behalf of the pharmaceutical industry since NAFTA 1.0. This analysis reviews the pharmaceutical related patent provisions of that text.
NAFTA 2.0 is dramatically worse than NAFTA 1.0 as it would help pharmaceutical companies avoid generic competition and keep medicine prices high. The text closely mimics the language and structure of the original U.S.-proposed IP language in the Trans-Pacific Partnership Agreement (TPP) — now known as the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP). The TPP was fiercely criticized for the pharma-friendly patent-related provisions that put the health and well-being of people in the TPP countries at risk. Following the U.S. withdrawal from that agreement, many of those damaging provisions were suspended by the TPP11 countries.
NAFTA 2.0, however, incorporates almost all of these pro-monopoly pharma-friendly patent-related provisions. In some circumstances, it even goes beyond the original TPP. To comply with the terms of the Sept. 30 text, Mexico and Canada would need to change their existing laws to provide new exclusivities for pharmaceutical companies, which would limit generic competition and raise prescription drug costs. These terms would also lock the U.S. into policies that have contributed to making U.S. medicine prices the highest in the world.
The analysis below reviews the most controversial provisions that would affect pharmaceutical prices and availability of medicines in the U.S., Canada, and Mexico. It only covers some of the main obligations of the IP measures relating to patents and pharmaceutical or regulated products in the final text. It should be noted that the interpretation of this Chapter is also likely to depend on provisions in other NAFTA 2.0 chapters.
Read more (pdf)
We have experienced problems with sending the weekly newsletter and we have been working to resolve the issue
News from the movements
-
18-Feb-2019 No al TTIP
Declaración de la sociedad civil europea sobre las negociaciones comerciales entre la UE y los EE.UU.
Un tratado comercial de la UE con Trump socavaría los compromisos internacionales sobre el clima. -
18-Feb-2019 Friends of the Earth Europe
EU trade with Trump would undermine international climate commitments
Three years ago, widespread protests took place across Europe against a planned trade deal between the EU and the US. It was eventually halted. EU governments are now planning to agree terms to start negotiating a new transatlantic trade deal. -
12-Feb-2019 Le Monde
« Les droits des investisseurs ne doivent pas être mieux protégés que ceux des citoyens ou de la planète »
27 associations, syndicats et ONG appellent les députés européens à rejeter un projet d’accord commercial entre l’UE et Singapour, comparable au très contesté CETA. -
11-Feb-2019 OMAL
Euskal Herria se planta ante los tratados comerciales
Proponemos una serie de líneas de actuación para que las administraciones vascas hagan frente a los principales dispositivos de los tratados. -
7-Feb-2019 Biodiversidad en América Latina
Tratados de Libre Comercio: Instrumentos de desvío de poder que sojuzgan el Derecho
Este cuaderno de trabajo contiene fragmentos de textos, testimonios y entrevistas para repensar los efectos de los tratados de libre comercio y señalar sus nocivos efectos sobre la soberanía política, social económica y jurídica de las naciones. -
6-Feb-2019 M4
Organizaciones denuncian demanda de compañía minera estadounidense contra Guatemala y expresan su solidaridad con las comunidades que defienden la tierra y la vida en “La Puya”
Nos unimos en solidaridad con los residentes de San Pedro Ayampuc y San José del Golfo, quienes están profundamente preocupados por la grave amenaza que la mina representa para los suministros de agua, los ecosistemas y la calidad de vida en el área. -
6-Feb-2019 Stop ISDS
Sued for existing – ancient Romanian town on the frontline of the battle against ISDS
Today, the 6th of February 2019, the Romanian town of Roşia Montană celebrates its 1888th year of existence. Over the past 20 years, residents have fought against a proposed multi-billion dollar mining project. -
6-Feb-2019 Seattle to Brussels Network
Support the joint letter on the future of ISDS – EU-Singapore IPA vote
Civil society organisations urge Member of the European Parliament to not ratify EU - Singapore Investment Protection Agreement
bilaterals.org is a collaborative space to share information and support movements struggling against bilateral trade and investment deals which serve corporations, not people. Multilingual. Global. No one owns it. Open publishing. Get involved.
Comment on this article